8月13日主力资金净流出2934.93万元，近五日累计净流出9731.15万元。 风险提示：股市有风险，投资需谨慎。 海南海药8月13日股价报收6.20元，较前一交易日下跌1.27%。当日成交量为450581手，成交金额达2.79 亿元。 海南海药属于化学制药行业，主营业务涵盖药品研发、生产和销售。公司产品线包括抗生素、抗肿瘤 药、心血管药等多个治疗领域。 公司最新披露，目前正在进行氟非尼酮Ⅱ期临床数据分析工作。此外，公司有注射用头孢唑肟钠、罗沙 司他胶囊、地氯雷他定口服溶液三个药品被纳入国家医保局第十一批集采名单。 ...

格隆汇8月13日丨海南海药(000566.SZ)于投资者互动平台表示，目前公司正进行氟非尼酮Ⅱ期临床数据 分析工作，具体临床试验报告请关注公司披露的相关公告。 ...

截至2025年8月8日收盘，海南海药股价报6.32元，较前一交易日上涨0.01元，涨幅0.16%。当日成交量 为263462手，成交金额1.66亿元。 海南海药主要从事化学制药业务，涉及生物疫苗等领域。公司当前总市值为81.99亿元，流通市值73.69 亿元。 从资金流向来看，8月8日主力资金净流入423.86万元，但近五日主力资金整体呈现净流出状态，累计净 流出7577.70万元。 风险提示：股市有风险，投资需谨慎。 ...

从薪酬分布看，A股化学制剂公司CFO年薪平均值为104.48万元。经统计，处于50万以下、50万-100万、100万-200万、200万以上各区间的人数占比分别为18%、48%、22%、12%。 其中，年薪排行前三的CFO分别为迪哲医药的吕洪斌、丽珠集团的司燕霞、科伦药业的赖德贵，三人年薪分别为421.01万元、390.40万元、300万元。 从薪酬变动幅度看（仅统计任职两年以上CFO薪资数据），海南海药（维权）的许荣义2024年薪酬降幅最大，同比降幅达48.66%；艾力斯的王林薪酬增幅最大，同比涨幅达104.6%。 责任编辑：公司观察 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有87家上市化学制剂公司，其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场 ...

金融界8月5日消息，有投资者在互动平台向海南海药提问：请问截至2025年7月31日公司股东人数是多 少？谢谢。 公司回答表示：您好，截至2025年7月31日，公司股东户数为87,580。 ...

Core Viewpoint - Hainan Haiyao has been awarded the "ESG Carbon Path Practitioner Award" for its outstanding practices in environmental, social, and governance (ESG) areas, highlighting its commitment to sustainable development and social responsibility [1][4]. Group 1: Environmental Practices - The company implements an EHS strategic goal, focusing on clean production, resource conservation, and green low-carbon transformation, significantly reducing energy consumption and pollutant emissions [4]. - During the reporting period, Hainan Haiyao did not experience any major environmental pollution incidents, demonstrating effective energy-saving and emission-reduction results [4]. - The company is continuously pursuing circular transformation to achieve carbon neutrality [4]. Group 2: Social Responsibility - Hainan Haiyao emphasizes employee health and safety, achieving zero work-related injuries and fatalities for three consecutive years, maintaining a million-hour death rate of 0% [4]. - The company actively conducts occupational disease health checks covering nearly a thousand employees and provides professional medical services through its medical sector [4]. Group 3: Governance Structure - Hainan Haiyao has established a scientific compliance system, revising its compliance management measures to enhance decision-making transparency and effectively address grievances [4]. - The company has introduced 24 new anti-corruption measures to ensure transparency in power supervision and safeguard business integrity [4]. Group 4: Future Outlook - The company plans to continue implementing its "14th Five-Year" strategic plan, focusing on high-quality development, deepening green low-carbon transformation, and innovative research and development [5]. - Hainan Haiyao aims to accelerate its position as a leading domestic manufacturer of active pharmaceutical ingredients and intermediates while strengthening its ESG integration practices [5]. - The new journey of Hainan Haiyao will further consolidate its ESG leadership and create greater environmental and social value [5].

Group 1 - Hainan Free Trade Zone sector opened high but closed low, indicating a bearish trend [1] - Shennong Agricultural (300189) fell over 9%, reflecting significant market pressure [1] - Xinlong Holdings (000955) declined more than 8%, contributing to the overall downturn in the sector [1] - Hainan Ruize (002596) dropped over 7%, further indicating weakness in the market [1] - Other companies such as Haima Automobile (000572), Hainan Rubber (601118), and Hainan Haiyao (000566) also experienced declines [1]

Group 1 - The A-share market in Hainan Free Trade Zone is experiencing a continuous decline [1] - Shen Nong Agricultural Industry and Xinlong Holdings have both dropped over 7% [1] - Other companies such as Haima Automobile, Hainan Ruize, Jinpan Technology, and Hainan Haiyao are also following the downward trend [1]

Core Viewpoint - The implementation of tax exemption policies in Hainan Free Trade Port is expected to significantly boost various industries, with a focus on zero tariffs and enhanced trade facilitation [1] Industry Analysis - **Duty-Free Retail**: The expansion of duty-free policies post-closure will lead to growth in the duty-free retail sector as the range of duty-free products increases [2] - **Tourism and Hospitality**: The favorable policies are anticipated to attract more tourists to Hainan, thereby stimulating the local tourism and hotel industries [3] - **Port and Shipping**: The increased trade facilitation after the closure is expected to enhance port logistics business [4] - **Pharmaceutical Manufacturing**: As a key encouraged industry, pharmaceutical companies will benefit from tax exemptions related to processing and value addition [5] - **High-Tech Industry**: The focus on developing high-tech industries in the free trade port will provide multiple policy benefits to related companies [6] Beneficiary Companies - **China Duty Free Group (601888)**: As a leader in the duty-free industry, the company will directly benefit from the upgraded duty-free policies [7] - **Hainan Airport (600515)**: Being a key transportation hub, the company is expected to benefit from increased passenger and logistics flow [8] - **Strait Shipping (002320)**: As a leader in waterway transportation in Hainan, the company will benefit from enhanced trade facilitation [9] - **Hainan Haiyao (000566)**: The local pharmaceutical leader will enjoy the benefits of tax exemptions for processing and value addition [10] - **Hainan Shipping Group (603069)**: The company will benefit from the growth in the tourism industry [10]

Core Viewpoint - The legal opinion letter from Beijing Dacheng (Haikou) Law Firm confirms the legality of the procedures and qualifications related to the third extraordinary general meeting of shareholders of Hainan Haiyao Co., Ltd. in 2025, ensuring compliance with relevant laws and regulations [1][2][8]. Group 1: Meeting Procedures - The extraordinary general meeting was proposed and convened by the board of directors, with announcements made on July 8, 2025, detailing the meeting's time, location, and agenda [3][4]. - The meeting was held both in-person and via online voting, with specific time slots for network voting on July 23, 2025 [3][4]. Group 2: Attendance and Qualifications - The meeting had one shareholder present in person, representing 400,660,181 shares, while 640 shareholders participated via online voting, representing 44,340,554 shares, or 3.4177% of the total shares [4][5]. - The qualifications of the attending shareholders and their representatives were verified, ensuring compliance with legal and regulatory requirements [5][6]. Group 3: Proposals and Voting Results - The meeting included proposals that significantly impact the interests of minority investors, with separate voting counts for these shareholders [6][7]. - The voting results showed that 43,446,149 shares (97.9829%) were in favor of the proposals, with a small percentage opposing or abstaining [7][8]. - The overall voting results indicated that 443,217,506 shares (99.5993%) supported the proposals, confirming the legitimacy of the voting process [7][8].